GlassScriptPhysician profile
Robert Eric Rosemund
NPI 1700854890
$5,560.80
in general payments reported to CMS, 2019-2025
38 companies · $728 in 2025
The $728 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $290 · 2021: $773 · 2022: $1,001 · 2023: $912 · 2024: $812 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $851.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $720.95 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $459.70 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Abbvie INC. | $439.62 | 2019-2025 | Qulipta, Viberzi, Linzess |
| Glaxosmithkline, LLC. | $413.43 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $375.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $342.55 | 2019-2025 | Fasenra, Airsupra, Wainua |
| Merck Sharp & Dohme LLC | $265.56 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $237.33 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.34 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $144.19 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $139.28 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $112.61 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.02 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.03 | 2019-2023 | Trintellix |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $79.71 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.19 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $65.78 | 2019-2024 | Spravato |
| Coloplast Corp | $37.19 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.04 | 2022 | |
| Supernus Pharmaceuticals, INC. | $34.65 | 2019 | |
| Horizon Therapeutics Plc | $34.44 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $32.20 | 2021 | |
| Zyla Life Sciences, INC. | $28.68 | 2019 | |
| Noven Therapeutics, LLC | $24.74 | 2024 | Xelstrym |
| Tactile Systems Technology INC | $24.09 | 2025 | Nimbl, Flexitouch Plus |
| Sanofi Pasteur INC. | $24.00 | 2022 | |
| Bausch Health US, LLC | $21.38 | 2019 | |
| Vivus LLC | $19.35 | 2022 | |
| Gilead Sciences, INC. | $19.15 | 2019 | |
| Corium, LLC | $19.02 | 2025 | Azstarys |
| Hikma Pharmaceuticals USA | $18.55 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.55 | 2021 | |
| Allergan, INC. | $17.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.57 | 2019 | |
| Dexcom, INC. | $14.44 | 2022 | |
| Shield Therapeutics INC | $13.22 | 2022 | |
| Redhill Biopharma INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rosemund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.